Conatus Pharmaceuticals is a biotechnology company focused on the development and commercialization of novel medicines to treat chronic diseases with significant unmet need. The Company's lead in-licensed compound, emricasan, is being developed in collaboration with Novartis for the treatment of patients with NASH-driven chronic liver diseases. In addition, Conatus' lead internally developed compound, CTS-2090, is targeting the treatment of patients with chronic diseases involving inflammasome pathways. Source
No articles found.
bluebird bio is pioneering gene therapy with purpose. From our Cambridge, Mass., h...
bluebird bio is pioneering gene therapy with pu...
The Juhi Ash Center, located on Fifth Avenue and 61st Street, combines the best of...
The Juhi Ash Center, located on Fifth Avenue an...
ALR Technologies is a medical device company providing remote monitoring and care ...
ALR Technologies is a medical device company pr...
Motif Bio is a clinical stage biopharmaceutical company developing novel antibioti...
Motif Bio is a clinical stage biopharmaceutical...
Magenta Therapeutics is a clinical-stage biotechnology company developing therapeu...
Magenta Therapeutics is a clinical-stage biotec...
Mirum Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused o...
Mirum Pharmaceuticals Inc. is a clinical-stage ...
Cyclerion Therapeutics is a clinical-stage biopharmaceutical company harnessing th...
Cyclerion Therapeutics is a clinical-stage biop...
Join the National Investor Network and get the latest information with your interests in mind.